AxoGen logo
AxoGen AXGN
$ 47.1 1.7%
report update icon

Quarterly report 2026-Q2
added 07-29-2026

AxoGen Financial Statements 2025-2009 | AXGN

Annual Financial Statements AxoGen

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

1.5 B 859 M 391 M 356 M 385 M 883 M 502 M 604 M 918 M 315 M 129 M 61 M 52.5 M 38.8 M 12.1 M 3.8 M -

Shares

46.1 M 44.3 M 42.9 M 42.1 M 41.2 M 40 M 39.2 M 37.1 M 33.3 M 30.7 M 26.1 M 17.7 M 13.5 M 11.1 M 3.7 M 1.21 M -

Historical Prices

32.5 19.4 9.13 8.45 9.34 22.1 12.4 18.5 29.2 10.4 5.2 3.17 4.04 3.95 2.86 3.15 4

Net Income

-15.7 M -9.96 M -21.7 M -28.9 M -27 M -23.8 M -29.1 M -22.4 M -10.4 M -14.4 M -13.4 M -17.7 M -14.6 M -9.42 M -9.22 M -5.42 M -

Revenue

225 M 187 M 159 M 139 M 127 M 112 M 107 M 83.9 M 60.4 M 41.1 M 27.3 M 16.8 M 10.9 M 7.69 M 4.85 M 3 M -

Cost of Revenue

57.9 M 45.4 M 37.1 M 29.8 M 22.9 M 21.6 M 17.3 M 12.9 M 9.31 M 6.47 M - - - - - - -

Gross Profit

167 M 142 M 122 M 109 M 104 M 90.7 M 89.4 M 71 M 51.1 M 34.6 M 22.5 M 13.4 M 8.51 M 5.73 M 2.42 M 1.63 M -

Operating Income

-7.85 M -3.29 M -21.5 M -29.7 M -25.4 M -23.2 M -31.4 M -20.5 M -7.95 M -8.13 M -9.27 M -9.8 M -9.59 M -7.8 M -6.97 M -4.48 M -

Interest Expense

167 K -199 K 2.84 M 624 K 1.36 M 1.05 M 40 K 1.21 M 2.22 M 5.39 M 3.99 M 6.81 M 4.82 M 1.39 M 1.09 M 815 K -

EBITDA

-1.19 M 3.18 M -17.2 M -26.9 M -22.7 M -21.7 M -28.5 M -19.6 M -7.38 M -7.69 M -9.02 M -9.6 M -9.45 M -7.49 M -6.63 M -4.18 M -

Operating Expenses

- - - - - - 121 M 91.5 M 59.1 M 42.8 M 31.7 M 23.2 M 18.1 M 13.5 M 9.39 M - -

General and Administrative Expenses

44.6 M 39 M 38.4 M 40.9 M 32.3 M 26.4 M 31.3 M 23.1 M 14.7 M 10.1 M 8.42 M 6.95 M 5.72 M 5.22 M 4.32 M 2.66 M -

All numbers in USD currency

Quarterly Income Statement AxoGen

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

53.3 M 51.6 M 47.2 M 46.5 M 46.1 M 45.2 M 44.1 M 43.9 M 43.7 M 43.2 M 43.1 M 43 M 42.9 M 42.6 M 42.4 M 42.2 M 42 M 41.8 M 41.7 M 41.5 M 41.1 M 40.7 M 40.6 M 40.1 M 39.8 M 39.7 M 39.6 M 39.3 M 39.2 M 38.9 M 38.9 M 38.5 M 36.7 M 34.5 M 34.4 M 33.3 M 33.1 M 33 M 33 M 30.2 M 30.1 M 30 M 30 M 26.8 M 24.9 M 22.5 M 19.5 M 17.5 M 17.5 M 17.4 M 17.3 M 14.3 M 11.1 M 11.1 M 11.1 M 11.1 M 11.1 M 11.1 M 11.1 M 11.1 M 4.31 M 11.1 M

Net Income

-1.52 M -19.6 M - 708 K 579 K -3.83 M - -1.86 M -1.92 M -6.64 M - -4.09 M -6.66 M -7.07 M - -4.32 M -7.74 M -11.5 M - -7.14 M -7.9 M -6.66 M -6.01 M -1.48 M -8.1 M -8.19 M -7.04 M -5.57 M -7.02 M -9.5 M -5.22 M -4.1 M -7.43 M -5.64 M -2.5 M -2.12 M -2.06 M -3.76 M -5.63 M -2.31 M -2.8 M -3.68 M - -2.98 M -3.19 M -3.58 M - -3.24 M -3.74 M -4.24 M - -3.55 M -3.46 M -3.44 M - -2.24 M -1.03 M -2.11 M - -3.11 M -1.68 M -2.29 M

Revenue

69.7 M 61.5 M - 60.1 M 56.7 M 48.6 M - 48.6 M 47.9 M 41.4 M - 41.3 M 38.2 M 36.7 M - 37 M 34.5 M 31 M - 31.2 M 33.6 M 31 M 32.5 M 33.4 M 22.1 M 24.3 M 28.2 M 28.6 M 26.7 M 23.3 M 23.4 M 22.7 M 20.6 M 17.3 M 17 M 16 M 15.2 M 12.2 M 11.4 M 11.2 M 10.4 M 8.11 M - 8.15 M 6.42 M 4.95 M - 4.67 M 4.21 M 3.14 M - 2.96 M 2.86 M 2.14 M - 1.98 M 2.01 M 1.65 M - 1.14 M 1.23 M 1.12 M

Cost of Revenue

19.1 M 15.3 M - 14.1 M 14.6 M 13.6 M - 12.2 M 12.6 M 8.76 M - 9.57 M 8.5 M 8.17 M - 6.18 M 6.28 M 5.55 M - 5.24 M 7.09 M 5.17 M - 5.7 M 5.6 M 4.82 M - 4.51 M 4.24 M 3.71 M - 3.46 M 3.11 M 2.71 M - - - - - - - - - - - - - - - - - - - - - - - - - 1.19 M - -

Gross Profit

50.7 M 46.2 M - 46 M 42 M 34.9 M - 36.4 M 35.3 M 32.6 M - 31.7 M 29.7 M 28.5 M - 30.8 M 28.2 M 25.5 M - 26 M 26.5 M 25.9 M 27 M 27.7 M 16.5 M 19.4 M 23.3 M 24.1 M 22.5 M 19.6 M 19.8 M 19.2 M 17.5 M 14.5 M 14.4 M 13.5 M 12.9 M 10.3 M 9.58 M 9.51 M 8.85 M 6.71 M - 6.74 M 5.38 M 3.97 M - 3.78 M 3.33 M 2.44 M - 2.31 M 2.23 M 1.58 M - 1.44 M 1.51 M 1.21 M - 10.4 K 801 K 783 K

Operating Income

-2.16 M -2.83 M - 1.91 M 1.67 M -1.66 M - -316 K -428 K -4.56 M - -4.02 M -6.9 M -7.34 M - -4.86 M -7.92 M -11.3 M - -6.69 M -7.15 M -6.22 M - -1.04 M -8.25 M -8.51 M - -6.11 M -7.67 M -10.2 M - -4.84 M -4.82 M -4.99 M - -1.5 M -1.45 M -3.2 M - -1.18 M -1.61 M -2.62 M - -1.92 M -2.15 M -2.54 M - -1.8 M -2.3 M -2.99 M - -2.28 M -2.19 M -2.32 M - -2.04 M -1.59 M -1.94 M - -2.63 M -1.45 M -902 K

Interest Expense

-145 K 23 K - 25 K 179 K -37 K - -48 K 1 K -107 K - -6 K -277 K 16 K - 61 K 249 K 354 K - 417 K 565 K 444 K - 397 K 31 K 31 K - -7 K 11 K 14 K - -16 K 544 K 586 K - 578 K 554 K 508 K 5.39 M 5.39 M 1.16 M 5.39 M - 1.04 M 1.02 M 995 K - 1.38 M 1.39 M 1.19 M - 1.21 M 1.22 M 1.07 M - 145 K 125 K 125 K - 318 K 406 K 203 K

EBITDA

1.06 M -1.23 M - 6.94 M 3.33 M 67 K - 1.34 M 1.23 M -3.04 M - -2.87 M -6.1 M -6.63 M - -4.09 M -7.21 M -10.6 M - -4.63 M -6.52 M -5.45 M - -671 K -7.94 M -8.2 M - -5.92 M -7.44 M -9.99 M - -4.64 M -4.62 M -4.81 M - -1.37 M -1.34 M -3.09 M - -919 K -1.44 M -2.54 M - -1.78 M -2.07 M -2.5 M - -1.69 M -2.23 M -2.96 M - -2.22 M -2.15 M -2.3 M - -1.9 M -1.48 M -1.89 M - -2.41 M -1.3 M -827 K

General and Administrative Expenses

13.4 M 12.9 M - 10.8 M 9.69 M 9.46 M - 10.8 M 9.42 M 9.96 M - 9.87 M 10.6 M 10.1 M - 8.8 M 9.4 M 9.62 M - 7.88 M 8.67 M 8.36 M - 6.82 M 6.4 M 5.5 M - 7.74 M 7.38 M 9.2 M - 6.07 M 5.67 M 5.01 M - 3.78 M 3.38 M 3.5 M - 2.48 M 2.74 M 2.14 M - 2.21 M 1.98 M 1.91 M - 1.65 M 1.71 M 1.89 M - 1.23 M 1.4 M 1.61 M - 1.39 M 1.15 M 1.23 M - 1.3 M 1.2 M 722 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements AxoGen AXGN
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting AxoGen plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Inogen Inogen
INGN
$ 5.45 1.11 % $ 145 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 125.5 0.15 % $ 4.36 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 22.59 1.17 % $ 530 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 81.2 2.79 % $ 4.43 B britainBritain
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.48 0.71 % $ 618 M israelIsrael
LENSAR LENSAR
LNSR
$ 8.25 0.06 % $ 98.7 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.05 0.67 % $ 398 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Myomo Myomo
MYO
$ 1.4 1.42 % $ 58.6 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Nano-X Imaging Ltd. Nano-X Imaging Ltd.
NNOX
$ 0.71 1.3 % $ 46 M israelIsrael
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
PAVmed PAVmed
PAVM
$ 5.09 0.19 % $ 3.41 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 150.58 1.65 % $ 10.6 B usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 2.58 3.98 % $ 110 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 10.94 1.67 % $ 305 M australiaAustralia
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.35 0.94 % $ 21.8 M usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 1.54 1.32 % $ 4.27 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA